Company intelligence / Profile preview

Benepet Biomedical

Ownership: Private
Development stage: Other

Overview

Benepet Biomedical develops proprietary probiotic/prebiotic blends to improve pet health by modulating gut microflora. Their formulations are used as supplements in food or aquatic environments to enhance disease resistance, reproduction, longevity, and ease maintenance. The company has transitioned from vermiculture research to a broader focus on microbiomic solutions for pets since 2014. No clinical trial data is reported; efficacy is based on field use and internal R&D.

Therapeutic areas: EndocrinologyInfectious DiseasesOther
Modalities: ProbioticsPrebioticsMicrobial blends
Industry: Veterinary

Beyond the preview

Go deeper on Benepet Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Benepet Biomedical.

Explore the full profile